Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents.
Cai S, Moutal A, Yu J, Chew LA, Isensee J, Chawla R, Gomez K, Luo S, Zhou Y, Chefdeville A, Madura C, Perez-Miller S, Bellampalli SS, Dorame A, Scott DD, François-Moutal L, Shan Z, Woodward T, Gokhale V, Hohmann AG, Vanderah TW, Patek M, Khanna M, Hucho T, Khanna R. Cai S, et al. Among authors: bellampalli ss. Sci Transl Med. 2021 Nov 10;13(619):eabh1314. doi: 10.1126/scitranslmed.abh1314. Epub 2021 Nov 10. Sci Transl Med. 2021. PMID: 34757807
A modulator of the low-voltage-activated T-type calcium channel that reverses HIV glycoprotein 120-, paclitaxel-, and spinal nerve ligation-induced peripheral neuropathies.
Cai S, Tuohy P, Ma C, Kitamura N, Gomez K, Zhou Y, Ran D, Bellampalli SS, Yu J, Luo S, Dorame A, Yen Ngan Pham N, Molnar G, Streicher JM, Patek M, Perez-Miller S, Moutal A, Wang J, Khanna R. Cai S, et al. Among authors: bellampalli ss. Pain. 2020 Nov;161(11):2551-2570. doi: 10.1097/j.pain.0000000000001955. Pain. 2020. PMID: 32541387 Free PMC article.
Reversal of Peripheral Neuropathic Pain by the Small-Molecule Natural Product Physalin F via Block of CaV2.3 (R-Type) and CaV2.2 (N-Type) Voltage-Gated Calcium Channels.
Shan Z, Cai S, Yu J, Zhang Z, Vallecillo TGM, Serafini MJ, Thomas AM, Pham NYN, Bellampalli SS, Moutal A, Zhou Y, Xu GB, Xu YM, Luo S, Patek M, Streicher JM, Gunatilaka AAL, Khanna R. Shan Z, et al. Among authors: bellampalli ss. ACS Chem Neurosci. 2019 Jun 19;10(6):2939-2955. doi: 10.1021/acschemneuro.9b00166. Epub 2019 Apr 18. ACS Chem Neurosci. 2019. PMID: 30946560
Dissecting the role of the CRMP2-neurofibromin complex on pain behaviors.
Moutal A, Wang Y, Yang X, Ji Y, Luo S, Dorame A, Bellampalli SS, Chew LA, Cai S, Dustrude ET, Keener JE, Marty MT, Vanderah TW, Khanna R. Moutal A, et al. Among authors: bellampalli ss. Pain. 2017 Nov;158(11):2203-2221. doi: 10.1097/j.pain.0000000000001026. Pain. 2017. PMID: 28767512 Free PMC article.
CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide.
Moutal A, Yang X, Li W, Gilbraith KB, Luo S, Cai S, François-Moutal L, Chew LA, Yeon SK, Bellampalli SS, Qu C, Xie JY, Ibrahim MM, Khanna M, Park KD, Porreca F, Khanna R. Moutal A, et al. Among authors: bellampalli ss. Pain. 2017 Dec;158(12):2301-2319. doi: 10.1097/j.pain.0000000000001002. Pain. 2017. PMID: 28809766 Free PMC article.
(-)-Hardwickiic Acid and Hautriwaic Acid Induce Antinociception via Blockade of Tetrodotoxin-Sensitive Voltage-Dependent Sodium Channels.
Cai S, Bellampalli SS, Yu J, Li W, Ji Y, Wijeratne EMK, Dorame A, Luo S, Shan Z, Khanna M, Moutal A, Streicher JM, Gunatilaka AAL, Khanna R. Cai S, et al. Among authors: bellampalli ss. ACS Chem Neurosci. 2019 Mar 20;10(3):1716-1728. doi: 10.1021/acschemneuro.8b00617. Epub 2018 Dec 20. ACS Chem Neurosci. 2019. PMID: 30525440
Phosphorylated CRMP2 Regulates Spinal Nociceptive Neurotransmission.
Yu J, Moutal A, Dorame A, Bellampalli SS, Chefdeville A, Kanazawa I, Pham NYN, Park KD, Weimer JM, Khanna R. Yu J, et al. Among authors: bellampalli ss. Mol Neurobiol. 2019 Jul;56(7):5241-5255. doi: 10.1007/s12035-018-1445-6. Epub 2018 Dec 18. Mol Neurobiol. 2019. PMID: 30565051 Free PMC article.
Targeting the CaVα-CaVβ interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy.
Khanna R, Yu J, Yang X, Moutal A, Chefdeville A, Gokhale V, Shuja Z, Chew LA, Bellampalli SS, Luo S, François-Moutal L, Serafini MJ, Ha T, Perez-Miller S, Park KD, Patwardhan AM, Streicher JM, Colecraft HM, Khanna M. Khanna R, et al. Among authors: bellampalli ss. Pain. 2019 Jul;160(7):1644-1661. doi: 10.1097/j.pain.0000000000001524. Pain. 2019. PMID: 30933958 Free PMC article.
22 results